Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($0.15), $0.62 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight